LONDON, Feb. 6, 2024
/PRNewswire/ -- Curaleaf International (the "Company"), part of
Curaleaf Holdings (TSX:CURA) and Europe's largest vertically integrated
cannabis company, is pleased to announce its acquisition of
Can4Med, a prominent pharmaceutical wholesaler specializing in
cannabinoid medications in Poland.
This strategic move marks a significant milestone for both
companies and underscores Curaleaf's commitment to enhancing
patient access to high-quality medical cannabis products across
Europe. Poland boasts one of
Europe's largest patient
populations seeking medical cannabis; by joining forces with
Can4Med, Curaleaf International gains a strong foothold in this
dynamic market, allowing it to serve patients more effectively and
expand its product offerings.
"This acquisition represents a significant step forward for
Curaleaf International. Poland's
medical cannabis market is expanding rapidly, and our partnership
with Can4Med allows us to better serve patients while driving
growth across Europe," said
Matt Darin, CEO of Curaleaf.
"We are thrilled that Can4med, a pioneering force in
Poland's cannabis market, has
joined forces with Curaleaf, the global leader in cannabis. This
acquisition marks a significant milestone in our journey, ensuring
an unparalleled supply chain that positions us to meet and exceed
the demands of the entire Polish market. Partnering with Curaleaf
not only reinforces our commitment to quality and accessibility but
also signifies a new era of growth and possibilities for both
companies and our customers," said Maximilian Weinberg, founder of Can4med.
As Poland positions itself at
the forefront of the European cannabis market, its substantial
population of 38 million is poised to catalyze significant growth
and innovation in the sector. The Polish Pharmaceutical Chamber
estimates that the potential number of medical cannabis users could
reach 300,000, while the number of legal cannabis users (both
medical and CBD) is expected to reach 1.3 million by 2026.
In 2023 alone, the country witnessed a remarkable surge in
medical cannabis adoption, with over 3,000KG distributed in
Poland, reflecting a growing acceptance and recognition of its
therapeutic benefits. This development is supported by an extensive
network of medical professionals authorized to prescribe cannabis.
Despite the complex registration process that producers and
patients must navigate, Curaleaf International, through its
subsidiary Four 20 Pharma GmbH, has emerged as a leading force,
securing its position as one of the only licensed producers in
the Polish market. This exclusive status underscores Curaleaf's
strategic foresight and commitment to meeting the rigorous
compliance and quality standards required to operate in this
burgeoning market, setting a benchmark for excellence and
reliability in the European cannabis industry.
About Curaleaf International: Curaleaf
International, a subsidiary of Curaleaf Holdings, is Europe's largest vertically integrated
cannabis company. With a strong track record of product innovation
and regulatory compliance, Curaleaf International has established
itself as a trusted provider of cannabis-based medicines in key
European markets.
About Can4Med: Can4Med is an experienced
pharmaceutical wholesaler specializing in the acquisition,
registration, and distribution of medical cannabis and products
containing THC and other cannabinoids in Poland. The company's
focus on importing and distributing cannabinoid medications has
positioned it as a critical link in the supply chain, ensuring
patients have access to safe and effective treatments. Can4Med
holds a pharmaceutical wholesaler license which permits the
marketing and distribution of narcotics for medical purposes and
allows the wholesaling of medicinal products and pharmaceutical raw
materials for pharmacy prescriptions. Backed by an experienced and
knowledgeable management team and staff, Can4Med is well-positioned
to register and distribute cannabis products
throughout Poland.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX:
CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international
provider of consumer products in cannabis with a mission to enhance
lives by cultivating, sharing and celebrating the power of the
plant. As a high-growth cannabis company known for quality,
expertise and reliability, the Company and its brands, including
Curaleaf, Select, and Grassroots provide industry-leading service,
product selection and accessibility across the medical and adult
use markets. In the United States,
our brands are sold in 17 states with operations encompassing 147
dispensaries and employing more than 5,200 team members. Curaleaf
International is the largest vertically integrated cannabis company
in Europe with a unique supply and
distribution network throughout the European market, bringing
together pioneering science and research with cutting-edge
cultivation, extraction and production. Curaleaf is listed on the
Toronto Stock Exchange under the symbol CURA and trades on the
OTCQX market under the symbol CURLF.
Forward Looking Statements
This media advisory
contains forward-looking statements and forward-looking information
within the meaning of applicable securities laws. These statements
relate to future events or future performance. All statements other
than statements of historical fact may be forward–looking
statements or information. Generally, forward-looking statements
and information may be identified by the use of forward-looking
terminology such as "plans", "expects" or, "proposed", "is
expected", "intends", "anticipates", or "believes", or variations
of such words and phrases, or by the use of words or phrases which
state that certain actions, events or results may, could, would, or
might occur or be achieved. More particularly and without
limitation, this news release contains forward-looking statements
and information concerning the expansion of the Company's medical
cannabis product portfolio in Poland. Such forward-looking statements and
information reflect management's current beliefs and are based on
assumptions made by and information currently available to the
company with respect to the matter described in this new release.
Forward-looking statements involve risks and uncertainties, which
are based on current expectations as of the date of this release
and subject to known and unknown risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statements. Additional information about these
assumptions and risks and uncertainties is contained under "Risk
Factors and Uncertainties" in the Company's latest annual
information form filed May 1, 2023,
which is available under the Company's SEDAR profile at
http://www.sedar.com, and in other filings that the Company has
made and may make with applicable securities authorities in the
future. Forward-looking statements contained herein are made only
as to the date of this press release and we undertake no obligation
to update or revise any forward-looking statements whether as a
result of new information, future events or otherwise, except as
required by law. We caution investors not to place considerable
reliance on the forward looking statements contained in this press
release. The Canadian Securities Exchange has not reviewed,
approved or disapproved the content of this news release.
INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment
Officer
IR@curaleaf.com
MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate
Communications
media@curaleaf.com
Curaleaf International
Email: press@curaleafinternational.com
Phone: +44 20 1234 5678
View original
content:https://www.prnewswire.com/news-releases/curaleaf-international-acquires-can4med-expanding-presence-in-polands-growing-medical-cannabis-market-302054778.html
SOURCE Curaleaf Holdings, Inc.